Name:
1-s2.0-S2211383521003075-main.pdf
Size:
3.927Mb
Format:
PDF
Description:
Final Published Version
Affiliation
Department of Pharmacology and Toxicology, College of Pharmacy, The University of ArizonaIssue Date
2021Keywords
2C proteinAcute flaccid myelitis
Antivirals
Enterovirus A71
EV-A71
Foot and mouth disease (HFMD)
Hand
Picornavirus
Metadata
Show full item recordPublisher
Chinese Academy of Medical SciencesCitation
Wang, J., Hu, Y., & Zheng, M. (2021). Enterovirus A71 antivirals: Past, present, and future. Acta Pharmaceutica Sinica B.Journal
Acta Pharmaceutica Sinica BRights
Copyright © 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hostingby Elsevier B.V. This is an open access article under the CC BY NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Enterovirus A71 (EV-A71) is a significant human pathogen, especially in children. EV-A71 infection is one of the leading causes of hand, foot, and mouth diseases (HFMD), and can lead to neurological complications such as acute flaccid myelitis (AFM) in severe cases. Although three EV-A71 vaccines are available in China, they are not broadly protective and have reduced efficacy against emerging strains. There is currently no approved antiviral for EV-A71. Significant progress has been made in developing antivirals against EV-A71 by targeting both viral proteins and host factors. However, viral capsid inhibitors and protease inhibitors failed in clinical trials of human rhinovirus infection due to limited efficacy or side effects. This review discusses major discoveries in EV-A71 antiviral development, analyzes the advantages and limitations of each drug target, and highlights the knowledge gaps that need to be addressed to advance the field forward. © 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.Note
Open access journalISSN
2211-3835Version
Final published versionae974a485f413a2113503eed53cd6c53
10.1016/j.apsb.2021.08.017
Scopus Count
Collections
Except where otherwise noted, this item's license is described as Copyright © 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hostingby Elsevier B.V. This is an open access article under the CC BY NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).